AZD0780, a Novel Oral PCSK9 Inhibitor, Demonstrated Significant LDL Cholesterol (LDL-C) Reduction in PURSUIT Phase IIb Trial
April 01, 2025
April 01, 2025
WILMINGTON, Delaware, April 1 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial
New late-breaking clinical trial data presented at ACC and published simultaneously in JACC show benefit of investigational medicine AZD0780 on top of standard of care
Positive results from the PURSUIT Phase . . .
* * *
AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial
New late-breaking clinical trial data presented at ACC and published simultaneously in JACC show benefit of investigational medicine AZD0780 on top of standard of care
Positive results from the PURSUIT Phase . . .